Equillium (EQ) Other Non Operating Income (2019 - 2026)
Equillium (EQ) posted quarterly Other Non Operating Income of $299000.0 for Q1 2026, up 38.43% year-over-year from $216000.0 in Q1 2025, and up 69.89% quarter-over-quarter from $176000.0 in Q4 2025.
Equillium (EQ) Other Non Operating Income (2019 - 2026) Analysis & Trends
Equillium (EQ) has reported Other Non Operating Income for 8 consecutive years, with $299000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income rose 38.43% year-over-year to $299000.0; the TTM figure through Mar 2026 stood at $1.3 million (up 434.29% YoY), while the FY2025 annual figure was $1.2 million, up 1308.05% from the prior year.
- Other Non Operating Income advanced to $299000.0 in Q1 2026 per EQ's latest filing, from $176000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $1.3 million in Q4 2022 and bottomed at -$1.6 million in Q4 2023.
- Historically, Other Non Operating Income has averaged $67294.1 across 5 years, with a median of $216000.0 in 2025.
- On a YoY basis, Other Non Operating Income climbed as much as 5927.27% in 2022 and fell as far as 558.62% in 2022.
- Equillium's Other Non Operating Income stood at $1.3 million in 2022, then sank by 222.25% to -$1.6 million in 2023, then gained by 25.29% to -$1.2 million in 2024, then jumped by 114.53% to $176000.0 in 2025, then jumped by 69.89% to $299000.0 in 2026.
- Business Quant data shows EQ's Other Non Operating Income at $299000.0 in Q1 2026, $176000.0 in Q4 2025, and $345000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Equillium | 263.86 Mn | 263.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 462,000.00 |
| Mar 31, 2026 | 299,000.00 |
| Dec 31, 2025 | 176,000.00 |
| Sep 30, 2025 | 345,000.00 |
| Jun 30, 2025 | 489,000.00 |
| Mar 31, 2025 | 216,000.00 |
| Dec 31, 2024 | -1.21 Mn |
| Sep 30, 2024 | 672,000.00 |
| Jun 30, 2024 | 568,000.00 |
| Mar 31, 2024 | 57,000.00 |
| Dec 31, 2023 | -1.62 Mn |
| Sep 30, 2023 | 409,000.00 |
| Jun 30, 2023 | 256,000.00 |
| Mar 31, 2023 | -179,000.00 |
| Dec 31, 2022 | 1.33 Mn |
| Sep 30, 2022 | -418,000.00 |
| Jun 30, 2022 | -382,000.00 |
| Mar 31, 2022 | 142,000.00 |
| Dec 31, 2021 | 22,000.00 |
| Sep 30, 2021 | -163,000.00 |